{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:43Z","timestamp":1791613663779,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-025-04096-9","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:34:29Z","timestamp":1761978869000},"page":"4-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Smoldering multiple myeloma: advances in diagnosis and risk stratification, and evolving therapeutic strategies"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-7756","authenticated-orcid":false,"given":"Taku","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"13","key":"4096_CR1","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362\u20139. https:\/\/doi.org\/10.1056\/NEJMoa054494.","journal-title":"N Engl J Med"},{"issue":"12","key":"4096_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9(12):102. https:\/\/doi.org\/10.1038\/s41408-019-0263-z.","journal-title":"Blood Cancer J"},{"issue":"8","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564\u20139. https:\/\/doi.org\/10.1056\/NEJMoa01133202.","journal-title":"N Engl J Med"},{"issue":"3","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","volume":"123","author":"I Turesson","year":"2014","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123(3):338\u201345. https:\/\/doi.org\/10.1182\/blood-2013-05-505487.","journal-title":"Blood"},{"issue":"5","key":"4096_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working G","year":"2003","unstructured":"International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749\u201357.","journal-title":"Br J Haematol"},{"issue":"6","key":"4096_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121\u20137. https:\/\/doi.org\/10.1038\/leu.2010.60.","journal-title":"Leukemia"},{"issue":"12","key":"4096_CR7","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4096_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","volume":"29","author":"S Thorsteinsdottir","year":"2023","unstructured":"Thorsteinsdottir S, Gislason GK, Aspelund T, Rognvaldsson S, Oskarsson J, Sigurethardottir GA, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29(2):467\u201372. https:\/\/doi.org\/10.1038\/s41591-022-02183-6.","journal-title":"Nat Med"},{"issue":"25","key":"4096_CR9","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582\u201390. https:\/\/doi.org\/10.1056\/NEJMoa070389.","journal-title":"N Engl J Med"},{"issue":"24","key":"4096_CR10","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/nejm198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302(24):1347\u20139. https:\/\/doi.org\/10.1056\/nejm198006123022405.","journal-title":"N Engl J Med"},{"issue":"10","key":"4096_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6(10):e486. https:\/\/doi.org\/10.1038\/bcj.2016.100.","journal-title":"Blood Cancer J"},{"issue":"4","key":"4096_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2012.296","volume":"27","author":"JT Larsen","year":"2013","unstructured":"Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27(4):941\u20136. https:\/\/doi.org\/10.1038\/leu.2012.296.","journal-title":"Leukemia"},{"issue":"5","key":"4096_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc1106428","volume":"365","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365(5):474\u20135. https:\/\/doi.org\/10.1056\/NEJMc1106428.","journal-title":"N Engl J Med"},{"issue":"9","key":"4096_CR14","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/jco.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber MA, B\u00e4uerle T, Ayyaz S, Heiss C, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28(9):1606\u201310. https:\/\/doi.org\/10.1200\/jco.2009.25.5356.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4096_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.61","volume":"8","author":"G Mellgard","year":"2024","unstructured":"Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, et al. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere. 2024;8(3):e61. https:\/\/doi.org\/10.1002\/hem3.61.","journal-title":"Hemasphere"},{"issue":"4","key":"4096_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2214\/AJR.08.1633","volume":"192","author":"CP Shortt","year":"2009","unstructured":"Shortt CP, Gleeson TG, Breen KA, McHugh J, O\u2019Connell MJ, O\u2019Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192(4):980\u20136. https:\/\/doi.org\/10.2214\/AJR.08.1633.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"4096_CR17","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2021210048","volume":"3","author":"C Messiou","year":"2021","unstructured":"Messiou C, Porta N, Sharma B, Levine D, Koh DM, Boyd K, et al. Prospective evaluation of whole-body MRI versus FDG-PET\/CT for lesion detection in participants with myeloma. Radiol Imaging Cancer. 2021;3(5):e210048. https:\/\/doi.org\/10.1148\/rycan.2021210048.","journal-title":"Radiol Imaging Cancer"},{"issue":"12","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00277-009-0829-0","volume":"88","author":"S Lutje","year":"2009","unstructured":"Lutje S, de Rooy JW, Croockewit S, Koedam E, Oyen WJ, Raymakers RA. Role of radiography, MRI and FDG-PET\/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009;88(12):1161\u20138. https:\/\/doi.org\/10.1007\/s00277-009-0829-0.","journal-title":"Ann Hematol"},{"issue":"1","key":"4096_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","volume":"14","author":"NH Abdallah","year":"2024","unstructured":"Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024;14(1):9. https:\/\/doi.org\/10.1038\/s41408-024-00980-5.","journal-title":"Blood Cancer J"},{"key":"4096_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016083","author":"E Kastritis","year":"2025","unstructured":"Kastritis E, Solia I, Malandrakis P, Theodorakakou F, Ntanasis-Stathopoulos I, Kanellias N, et al. Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025016083.","journal-title":"Blood Adv"},{"issue":"1","key":"4096_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41408-024-01159-8","volume":"14","author":"A Werly","year":"2024","unstructured":"Werly A, Hampel M, Hielscher T, Zuern K, Schmidt SK, Visram A, et al. Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma. Blood Cancer J. 2024;14(1):176. https:\/\/doi.org\/10.1038\/s41408-024-01159-8.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4096_CR22","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9(1):3363. https:\/\/doi.org\/10.1038\/s41467-018-05058-y.","journal-title":"Nat Commun"},{"issue":"2","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33(2):457\u201368. https:\/\/doi.org\/10.1038\/s41375-018-0206-x.","journal-title":"Leukemia"},{"issue":"1","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021;12(1):293. https:\/\/doi.org\/10.1038\/s41467-020-20524-2.","journal-title":"Nat Commun"},{"issue":"7","key":"4096_CR25","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E Perez-Persona","year":"2007","unstructured":"Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586\u201392. https:\/\/doi.org\/10.1182\/blood-2007-05-088443.","journal-title":"Blood"},{"issue":"2","key":"4096_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785\u20139. https:\/\/doi.org\/10.1182\/blood-2007-08-108357.","journal-title":"Blood"},{"issue":"1","key":"4096_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","volume":"148","author":"E P\u00e9rez-Persona","year":"2010","unstructured":"P\u00e9rez-Persona E, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Las Heras N, de Coca AG, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148(1):110\u20134. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07929.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"4096_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","volume":"123","author":"L Rosi\u00f1ol","year":"2003","unstructured":"Rosi\u00f1ol L, Blad\u00e9 J, Esteve J, Aymerich M, Rozman M, Montoto S, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123(4):631\u20136. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04654.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"4096_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2012.237","volume":"27","author":"G Bianchi","year":"2013","unstructured":"Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680\u20135. https:\/\/doi.org\/10.1038\/leu.2012.237.","journal-title":"Leukemia"},{"issue":"8","key":"4096_CR30","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738\u201344. https:\/\/doi.org\/10.1038\/leu.2013.86.","journal-title":"Leukemia"},{"issue":"3","key":"4096_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4065\/mcp.2009.0653","volume":"85","author":"S Madan","year":"2010","unstructured":"Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc. 2010;85(3):300. https:\/\/doi.org\/10.4065\/mcp.2009.0653.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"4096_CR32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41375-022-01529-w","volume":"36","author":"A Visram","year":"2022","unstructured":"Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio >\/=100. Leukemia. 2022;36(5):1429\u201331. https:\/\/doi.org\/10.1038\/s41375-022-01529-w.","journal-title":"Leukemia"},{"issue":"6","key":"4096_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. https:\/\/doi.org\/10.1038\/s41408-018-0077-4.","journal-title":"Blood Cancer J"},{"issue":"10","key":"4096_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. https:\/\/doi.org\/10.1038\/s41408-020-00366-3.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4096_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41408-024-01170-z","volume":"14","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, et al. Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database. Blood Cancer J. 2024;14(1):215. https:\/\/doi.org\/10.1038\/s41408-024-01170-z.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4096_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41408-023-00906-7","volume":"13","author":"V Sandecka","year":"2023","unstructured":"Sandecka V, Popkova T, Stork M, Maisnar V, Minarik J, Jungova A, et al. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic registry of monoclonal gammopathies. Blood Cancer J. 2023;13(1):153. https:\/\/doi.org\/10.1038\/s41408-023-00906-7.","journal-title":"Blood Cancer J"},{"issue":"7","key":"4096_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6(7):e454. https:\/\/doi.org\/10.1038\/bcj.2016.65.","journal-title":"Blood Cancer J"},{"issue":"6","key":"4096_CR38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","volume":"32","author":"C Fern\u00e1ndez de Larrea","year":"2018","unstructured":"Fern\u00e1ndez de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia. 2018;32(6):1427\u201334. https:\/\/doi.org\/10.1038\/s41375-018-0013-4.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"4096_CR39","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2022-165371","volume":"140","author":"LG Rodr\u00edguez-Lobato","year":"2022","unstructured":"Rodr\u00edguez-Lobato LG, de Daniel i Bisbe A, Tovar N, Jim\u00e9nez-Segura R, Cibeira MT, Moreno DF, et al. Evolving pattern improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma. Blood. 2022;140(Supplement 1):4341\u20132. https:\/\/doi.org\/10.1182\/blood-2022-165371.","journal-title":"Blood"},{"issue":"3","key":"4096_CR40","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10(3):e203\u201312. https:\/\/doi.org\/10.1016\/S2352-3026(22)00386-6.","journal-title":"Lancet Haematol"},{"issue":"3","key":"4096_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/bf02983776","volume":"77","author":"S Iida","year":"2003","unstructured":"Iida S, Ueda R. Multistep tumorigenesis of multiple myeloma: its molecular delineation. Int J Hematol. 2003;77(3):207\u201312. https:\/\/doi.org\/10.1007\/bf02983776.","journal-title":"Int J Hematol"},{"issue":"1","key":"4096_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-022-00374-6","volume":"8","author":"A Mikulasova","year":"2022","unstructured":"Mikulasova A, Morgan GJ, Walker BA. Chromosomal abnormalities in multiple myeloma. Nat Rev Dis Primers. 2022;8(1):42. https:\/\/doi.org\/10.1038\/s41572-022-00374-6.","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"4096_CR43","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/jco.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38(21):2380\u20139. https:\/\/doi.org\/10.1200\/jco.20.00437.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4096_CR44","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1038\/s41467-022-30694-w","volume":"13","author":"M Bustoros","year":"2022","unstructured":"Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13(1):3449. https:\/\/doi.org\/10.1038\/s41467-022-30694-w.","journal-title":"Nat Commun"},{"issue":"19","key":"4096_CR45","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.Ccr-24-0210","volume":"30","author":"D Kazandjian","year":"2024","unstructured":"Kazandjian D, Diamond B, Papadimitriou M, Hill E, Sklavenitis-Pistofidis R, Ziccheddu B, et al. Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma. Clin Cancer Res. 2024;30(19):4482\u201390. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0210.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4096_CR46","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, L\u00f3pez-Corral L, et al. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood. 2016;127(9):1151\u201362. https:\/\/doi.org\/10.1182\/blood-2015-10-662320.","journal-title":"Blood"},{"issue":"5","key":"4096_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493\u2013506. https:\/\/doi.org\/10.1038\/s43018-020-0053-3.","journal-title":"Nat Cancer"},{"issue":"16","key":"4096_CR48","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.22.01916","volume":"41","author":"L Burgos","year":"2023","unstructured":"Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelinek T, et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies. J Clin Oncol. 2023;41(16):3019\u201331. https:\/\/doi.org\/10.1200\/JCO.22.01916.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4096_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749.","journal-title":"Blood"},{"issue":"5","key":"4096_CR50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1300439.","journal-title":"N Engl J Med"},{"issue":"8","key":"4096_CR51","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/s1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(16)30124-3.","journal-title":"Lancet Oncol"},{"key":"4096_CR52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","volume":"174","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Hernandez MT, Salvador C, Rubia J, de Arriba F, Lopez-Corral L, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12\u00a0years of median follow-up time: a randomized, open-label study. Eur J Cancer. 2022;174:243\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.030.","journal-title":"Eur J Cancer"},{"issue":"11","key":"4096_CR53","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126\u201337. https:\/\/doi.org\/10.1200\/JCO.19.01740.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4096_CR54","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00432-022-03920-7","volume":"148","author":"AS Ojo","year":"2022","unstructured":"Ojo AS, Ojukwu SG, Asemota J, Akinyemi O, Araoye MO, Saleh M, et al. The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials. J Cancer Res Clin Oncol. 2022;148(4):897\u2013911. https:\/\/doi.org\/10.1007\/s00432-022-03920-7.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4096_CR55","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.clml.2022.10.009","volume":"23","author":"AS Ojo","year":"2023","unstructured":"Ojo AS, Akinyemi O, Araoye MO, Ali A. Early intervention with a curative intent through an intensive therapy versus immunologic disease control using a minimal intensity approach in the management of high-risk smoldering multiple myeloma: a systematic review of evidence from clinical trials. Clin Lymphoma Myeloma Leuk. 2023;23(1):e27\u201340. https:\/\/doi.org\/10.1016\/j.clml.2022.10.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"4096_CR56","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. 2025;392(18):1777\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2409029.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"4096_CR57","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2022-168930","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar SK, Alsina M, Laplant B, Badros AZ, Abdallah A-O, Abonour R, et al. Fixed duration therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for high risk smoldering multiple myeloma-results of the Ascent trial. Blood. 2022;140(Supplement 1):1830\u20132. https:\/\/doi.org\/10.1182\/blood-2022-168930.","journal-title":"Blood"},{"issue":"27","key":"4096_CR58","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, et al. Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance. J Clin Oncol. 2024;42(27):3247\u201356. https:\/\/doi.org\/10.1200\/JCO.23.02771.","journal-title":"J Clin Oncol"},{"issue":"15","key":"4096_CR59","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood.2024025897","volume":"145","author":"O Landgren","year":"2025","unstructured":"Landgren O, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, et al. Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 2025;145(15):1658\u201369. https:\/\/doi.org\/10.1182\/blood.2024025897.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4096_CR60","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2023-177954","volume":"142","author":"O Nadeem","year":"2023","unstructured":"Nadeem O, Magidson S, Midha S, O\u2019Donnell EK, Hartley-Brown MA, Sperling AS, et al. Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma. Blood. 2023;142(Supplement 1):206. https:\/\/doi.org\/10.1182\/blood-2023-177954.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4096_CR61","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood-2024-202676","volume":"144","author":"O Nadeem","year":"2024","unstructured":"Nadeem O, Nikiforow S, DeBraganca K, Bosch-Vilaseca A, O\u2019Donnell EK, Sperling AS, et al. Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma. Blood. 2024;144(Supplement 1):1027. https:\/\/doi.org\/10.1182\/blood-2024-202676.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s12185-025-04123-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04096-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:08:27Z","timestamp":1782860907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04096-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04096-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to amend the column header in table 1.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-025-04123-9","URL":"https:\/\/doi.org\/10.1007\/s12185-025-04123-9","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TK received personal fees from Janssen Pharmaceuticals (Titusville, NJ, USA), Takeda (Osaka, Japan), Bristol-Myers Squibb (New York, NY, USA), Pfizer (New York, NY, USA), and Sanofi (Paris, France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}